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Normal epithelial thyroid cells in culture are inhibited by TGF-β1. Instead, transformed thyroid cell lines are frequently resistant
to its growth inhibitory eﬀect. Loss of TGF-β responsiveness could be due to a reduced expression of TGF-β receptors, as shown
in transformed rat thyroid cell lines and in human thyroid tumors, or to alterations of other genes controlling TGF-β signal
transduction pathway. However, in thyroid neoplasia, a complex pattern of alterations occurring during transformation and
progressionhas been identiﬁed. Functionally, TGF-β1 acts asa tumorsuppressorinthe early stageoftransformationorasa tumor
promoter in advanced cancer. This peculiar pleiotropic behaviour of TGF-β may result from cross-talk with signalling pathways
mediated by other growth factors, among which EGF-like ligands play an important role. This paper reports evidences on TGF-β1
and EGF systems in thyroid tumors and on the cross-talk between these growth factors in thyroid cancer.
1.Introduction
Thyroid gland homeostasis is maintained through a ﬁne
regulation of thyrocyte growth and diﬀerentiation. This
regulation occurs through complex interactions between
thyroid-stimulating hormone (TSH) and other growth
factors and cytokines [1]. Evidence supports the role of
transforming growth factor-beta 1 (TGF-β1) and epidermal
growth factor- (EGF-) like ligands in the regulation of
thyroidproliferationanddiﬀerentiation,giventhenumerous
information focused on mechanism of signal transduction
and cross-talk. It is emerging the concept that the basis
behind the pleiotropicnature ofTGF-β in the contextofcell-
type and tumorigenesis derived probably from diﬀerences in
the mechanism of such cross-talk.
The TGF-β superfamily, which includesTGF-βs,a c t i vi n s ,
and bone morphogenetic proteins (BMPs), is a multi-
functional dimeric proteins family that regulates growth,
diﬀerentiation and extracellular matrix production in many
diﬀerent cell types [2]. In epithelial cells, TGF-β acts as
a tumorsuppressorby inhibiting cell growth orby regulating
cellular diﬀerentiation or apoptosis.
EGF is the prototype of a large family of peptides that
consists of about a dozen members and has an essential role
in embryonicdevelopmentaswell asin inducingcellgrowth.
Mutations in the kinase domain of EGFR/ErbB1 (epidermal
growth factor receptor) and ErbB2 are responsible of ligand-
independent activation of cytoplasmic signal transducers
that regulate motility, adhesion, protection from apoptosis,
and transformation [3].
TGF-β and EGF are physiological regulators of thyroid
cell diﬀerentiation and proliferation. TGF-β is normally
expressed and secreted by thyrocytes, acting as a potent
inhibitor of thyroid cell growth [4]. EGF, instead, acts
as a strong mitogen for follicular thyroid cells [5]. Any
alterations of these two factors or their signalling pathways2 Journal of Thyroid Research
may play an important role in the stepwise transition
towards malignancy, including the ability to become, at
least partially, resistant to growth inhibition, to proliferate
without dependence on growth factors, to replicate without
limit,to invade,and tometastasize. TGF-β1appearstohavea
dual eﬀect in tumorigenesis. It can act as a tumor suppressor
in the pretumor stage, and as a tumor promoter in late stage
of tumorigenesis. It is likely that during tumorigenesis, as
a result of genetic and/or epigenetic changes, the balance
between those opposing functions ofTGF-β1c h a n g e sr e s u l t -
ing in a switch to tumor promotion; however, the precise
mechanism for this switch remains to be clariﬁed [6]. In this
paper we focused our attention on the role of EGF and TGF-
βinthecontrolofproliferationanddiﬀerentiationofthyroid
cells.
2.Thyroid CellRegulationby GrowthFactors
Physiological regulation of thyroid cell growth and function
involves a complex network of factors that act through
endocrine, paracrine, or autocrine mechanisms. The pro-
liferation and diﬀerentiation of thyroid epithelial cells are
under the control of a positive systemic signal, TSH, and a
negative locally produced signal, TGF-β.T h em a i nf u n c t i o n
of the thyroid is the formation, storage, and secretion of
thyroid hormones tightly controlled by TSH, but requiring
insulin/insulin-like growth factor I (IGF-I) [7]. The steps
leading to the thyroid hormone formation include thy-
roglobulin (TG) synthesis and transport to the lumen of
thyroid follicles, the iodide uptake by the sodium iodide
symporter (NIS), iodination of TG, and coupling of TG
iodotyrosine residues by the thyroperoxidase (TPO). In rat
thyroid cells, the expression of the TG, TPO, NIS, and TSH
receptor (TSHR) is under the control of thyroid-restricted
transcription factors, such as thyroid transcription factor-1
(TTF-1) [8], that plays the most important role in the
expression of all the genes, Pax-8, and TTF-2 [9, 10].
TSH, through the activation of its receptor, has been
shown to stimulate more than one signal transduction
pathway, the main of which being the adenylcyclase/cAMP
(cyclic adenosine monophosphate) pathway. cAMP seems to
account for the mitogenic eﬀects of TSH in human thyroid
cells, mediated by the activation of cAMP-dependentprotein
kinases [11]. TSH-induced cAMP also appears to play a
central role in iodide uptake and metabolism in the dog
follicular cells [12], in TG and TPO gene expression in rat
follicular cells [13] .A l t h o u g hT S Hi st h em a j o rr e g u l a t o r
of thyroid growth and functions, it has been shown that
an u m b e ro fg r o w t hf a c t o r sa ﬀect the proliferation and
function of thyroid epithelial cells. In fact, TSH eﬀects can
be potentiated by several growth factors such as insulin
and IGF-I in rat thyroid cells in culture [14]. Insulin or
IGF-I synergizes with TSH to induce thyroid cell growth
and to maintain specialized cell functions [11]. There is
evidencethatTSHR and TG gene expression are regulated by
insulin/IGF-I as well as TSH in a rat thyroid cell line (FRTL-
5) [15, 16]. Moreover, an important regulator of thyroid
growth that stimulates proliferation in vitro includes EGF.
3.EpidermalGrowthFactor-Related
LigandsandTheir Receptors
EGF isthe prototypeofa large family ofpeptidesstructurally
related by possessing an EGF-like domain that consists of 6
cysteine residues capable of forming three disulﬁde-bonded
intramolecular loops. These ligands are expressed in the
extracellular domain of transmembrane proteins and are
generated by regulated proteolysis to yield growth factors
that contain 49–85 amino acids. The components of the
EGF-likegrowthfactorsfamilyarefunctionallyrelatedonthe
basis of binding to the members of the tyrosine kinase ErbB
family (EGFR/ErbB1, ErbB2, ErbB3, and ErbB4) and are
divided into three groups: the ﬁrst includes EGF, transform-
ing growth factor-alpha (TGF-α) and amphiregulin, which
all bindspeciﬁcally toEGFR/ErbB1.Asecondgroupincludes
betacellulin, heparin-binding EGF (HB-EGF), and epireg-
ulin bindingto bothEGFR/ErbB1and ErbB4,while the third
group comprises the neuregulin family, diﬀerentiated by
theirbindingtoErbB3andErbB4(NRG1andNRG2)oronly
to ErbB4 (NRG3 and NRG4) [17]. All four human receptors
share fourextracellular domainswith high structuralhomol-
ogy, a single transmembrane spanning helix, and a cyto-
plasmic portion that contains a conserved but not equally
functional tyrosine kinase domain. Only the EGFR/ErbB1
and ErbB4arefully functional interms ofligand bindingand
kinase activity. ErbB2 fails to bind any of the known ErbB
ligands but contributes its potent kinase activity to all possi-
ble heterodimers. ErbB3 has an impaired kinase activity and
reliesonthekinaseactivityofitsheterodimerizationpartners
for activation. Heterodimers of ErbB2 and ErbB3 are the
most potent ErbB pair in mitogenic signalling [17–19].
After ligand binding, ErbB receptors achieve activation
byforming homo-orheterodimeric receptorcomplexes.The
dimerization of ErbB receptors represents the most impor-
tant mechanism that drives transformation. Dimeric recep-
torsbecomecatalyticallyactiveand are abletophosphorylate
the cytoplasmic receptor domain that serves as docking
site for a variety of signalling molecules whose recruitment
leads to the activation of intracellular pathways controlling
diverse geneticprograms. The two major signalling pathways
activatedbyErbBreceptorsarethemitogen-activated protein
kinases (MAPKs) pathway which stimulates proliferation,
and Phosphatidylinositol 3-kinases/AKT (PI3K-AKT) path-
way which promotes cell survival (Figure 1). The speciﬁc
combination of ErbB receptors in the dimer deﬁnes the
downstream signalling network as well as the intensity and
the duration of the stimulation. Indeed, heterodimers that
involve ErbB3 stimulates the activation of PI3K pathway
[20].
Ampliﬁcation, overexpression and gene mutation of
EGFR/ErbB1 and ErbB2 have been found in various human
cancers [17, 21]. EGFR/ErbB1 is overexpressed in blad-
der, breast, head and neck, kidney, nonsmall cell lung,
and prostate cancers [22]. Three truncated forms of the
EGFR/ErbB1 have been described [23]a m o n gw h i c ht h e
EGFRvIII (variant III) lacks the majority of the ectodomain
and does not bind EGF. This variant is the most common
in glioblastoma multiforme and also occurs in lung, breast,Journal of Thyroid Research 3
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Figure 1: Mechanisms of action of ErbB receptor. In tumor cells, ErbB receptor tyrosine kinases are activated by autocrine or paracrine
production of EGF family ligands. Autocrine ligand production results from the activation of G-protein coupled receptors (GPCRs)
or frizzled (FZD) receptor which causes the metalloproteinases-mediated cleavage and release of pro-EGF-related ligands (ectodomain
shedding). Binding of ligands to the extracellular domain of ErbB receptors leads to receptor dimerization, autophosphorylation, and
activation of several downstream signalling pathways. In particular, tyrosine-phosphorylated ErbB receptors bind the adaptor proteins Shc
and Grb2 leading to Sos recruitment and Ras/MAPK pathway activation. The PI3K/Akt pathway is stimulated through recruitment of the
p85 adaptor subunit of PI3K to the receptor.
ovarian, and prostate cancer [24]. ErbB2 protein is overex-
pressed in breast cancer due to gene ampliﬁcation in 15%–
30% of invasive ductal breast cancers and overexpression
correlates with poor prognosis and disease progression [25].
A number of studies have shown mutations in the kinase
domain of EGFR/ErbB1 and ErbB2 [3, 21]. Intragenic
somatic mutations in the ErbB2 gene were reported in 5% of
nonsmall cell lung cancer, 5% of gastric carcinomas, 3% of
colorectalcarcinomas, and 5% ofbreast carcinomas [26–28].
Accumulating evidence has suggested that also ErbB3 plays a
critical role in cancer. Overexpression of ErbB3 often accom-
panies EGFR/ErbB1 or ErbB2 overexpression and has been
frequently detected in a variety of cancers, including those
of the breast [29], colon [30], stomach [31], ovary [32], and
pancreas [33]. In ErbB2-driven cancers, ErbB3 functions as
an intimate signalling partner that promotes the transform-
ing potency of ErbB2, usually by activating the PI3K/AKT
pathway [34]. ErbB4 receptor is made in at least four
diﬀerent full-length isoforms as a consequence of alternative
mRNA splicing [35]. It has both oncogenic and tumor sup-
pressive functions. Supporting a role in promoting growth,
overexpression of ErbB4 enhances growth of human breast
cancer cells [36] and transforms mouse mammary epithelial
cells to form tumors in vitro and in vivo [37]. Supporting a
suppressive role for mammary tumor growth activation of
ErbB4 in breast cancer cells has been associated with cell-
cycle arrest, diﬀerentiation, and apoptosis in vitro [38].
4.EpidermalGrowthFactor-Related
LigandsandTheir ReceptorsinThyroid
EGF is synthesized by thyroid gland and is able to induce
thyroid cell proliferation in several species together with
the loss of thyroid speciﬁc functions [5]. Moreover, EGF
enhances the migration and invasiveness of papillary thyroid
cancer [5, 39–41]. Accordingly, in vitro growth was inhibited
when either neutralizing anti-TGF-α or anti-EGFR/ErbB1
antibodies were applied to thyroid carcinoma cell lines [42].
A correlation between the staining intensity of EGF and
recurrence has been found statistically signiﬁcant in a set
of human papillary thyroid tumors, indicating EGF as a
predictor of papillary thyroid carcinoma aggressiveness [43].
Follicular epithelial thyroid cells expressed weakly TGF-α
protein, whereas 66% of hyperplastic thyroid nodules, 100%
of thyroid adenocarcinomas, and all cases of papillary, fol-
licular, and medullary carcinomas displayed intense staining
for TGF-α. Aparallel pattern ofstaining was observedforthe
EGFR/ErbB1 in these tissues, suggesting the potential for an
in vivo autocrine loop [44]. Papillary carcinomas and their
lymph node metastases coexpressed EGFR/ErbB1 and EbB2
mRNA transcripts at a higher level than in normal thyroid
tissues [45]. Moreover, in the same histotype of cancer, it
has also been demonstrated the coexpression of TGF-α and
EGFR/ErbB1 mRNAtranscripts at higher levelsthan in non-
neoplastic thyroid tissues [46].4 Journal of Thyroid Research
Rat thyroid epithelial cells transformed with K-ras onco-
gene were found to express high levels of ErbB4 receptor
and Neuregulin-1 (HRG/NDF/NRG1) ligand compared to
rat thyroid epithelial control cells. Treatment of K-ras
transformed thyroid cells with neutralizing antibody against
NRG1 reduced by 50% cell proliferation, demonstrating
t h ep r e s e n c eo fa na c t i v eN R G 1p r o t e i ns e c r e t e di nt h e
supernatant by the cells. These data indicate that in K-
ras rat thyroid epithelial cells, the growth factor NRG1
signals through the heterodimer ErbB2/ErbB4 receptors in
an autocrine fashion [47]. Nevertheless, in human pap-
illary carcinomas the protein overexpression and nuclear
localization of the NRG1 precursor isoform compared to
normalthyroidtissueswasnotassociatedwiththeexpression
of ErbB receptors, while the expression of neuregulin-
β3( H r g β3) was signiﬁcantly correlated to ErbB3 protein
expression, indicating this receptor as the cognate one
[48].
EGFR/ErbB1washigherexpressed inanaplasticandpap-
illary thyroid cancers than in normal thyroid tissues. In par-
ticular, Bergstrom et al. [49] have shown that EGFR/ErbB1
was expressed in all six anaplastic thyroid carcinomas exam-
ined and it was constitutive phosphorylated in 3 of the 6 cell
lines tested. Song [50] has demonstrated that EGFR/ErbB1
was expressed in 90% of papillary carcinomas analyzed.
Moreover, the role of EGFR/ErbB1in stimulating the growth
of thyroid tumors has been highlighted by the capability
of Geﬁtinib, a small molecule inhibitor of EGFR/ErbB1, to
reduce the growth of papillary, follicular, and anaplastic thy-
roid cancer cells [51, 52]. By immunohistochemical analyses,
cytoplasmic immunopositivity of EGFR/ErbB1was observed
in papillary carcinomas, while no nuclear positivity for EGF
and EGFR/ErbB1 was demonstrated. A study by Akslen et al.
signiﬁcantly associated cytoplasmatic EGFR/ErbB1 with the
increased risk of recurrent tumor. Nuclear positivity for EGF
and EGFR/ErbB1 was demonstrated to be a feature of both
follicular adenomas and follicular carcinomas [53, 54].
The role of the ErbB2 proto-oncogene in thyroid car-
cinoma has been controversially discussed. It has been
reported that high levels of ErbB2 mRNA expression cor-
related with lymph node metastasis in papillary carcinoma
[45]. Studies by Utrilla et al. [55] and Haugen et al. [56]
showed that there are marked diﬀerences in the pattern of
ErbB2 immunoreactivity depending on the tumor type. The
investigators demonstrated positivity for papillary carcino-
mas and negativity for follicular adenomas and follicular
carcinomas, but they showed controversial results about
medullary carcinomas. Moreover, ErbB2 was not detected in
papillary carcinomas by immunohistochemistry [57]. Some
studies investigated ErbB2 correlation with prognosis. Sugg
et al. [58] found ErbB2 staining correlation with degree of
diﬀerentiation, while Gumurdulu et al. [59]d e m o n s t r a t e d
that further investigations on ErbB2 role in thyroid tumors
are required for determination of prognosis. Other studies
have associated cytoplasmatic reactivity with patient’s sex in
tumor [60] or with development of metastasis [61].
Few studies analyzed all ErbB family members and their
implication in thyroid tumors. Wiseman et al. [62]s h o w e d
that EGFR/ErbB1, ErbB2, ErbB3, and ErbB4 were expressed
in 76%, 2%, 57%, and 73% of diﬀerentiated thyroid carcino-
mas analyzed (90 cases of papillary and 6 cases of follicular
carcinomas examined), respectively. Moreover, EGFR/ErbB1
and ErbB3 showed signiﬁcantly increased expression, while
ErbB4 showed signiﬁcantly decreased expression in these
tumorscomparedwithbenignthyroidlesions.ErbB3expres-
sion correlated with the presence of lymph node metastases,
tumor type, and higher N stage; the expression of ErbB4
correlated with lower T stage. Kato et al. [63]d e m o n s t r a t e d
that the transcription level of ErbB2 and ErbB3 genes was
increased in papillary carcinomas compared to normal
tissues, suggesting that the expression of an ErbB2-ErbB3
heterodimer may correlate with the aggressiveness of a thy-
roid tumor. Interestingly, coexisting protein overexpression
ofEGFR/ErbB1,ErbB2,ErbB3,andErbB4wasdemonstrated
in 64% of papillary thyroid carcinomas providing numerous
possibilities for functional receptor interactions [64].
5.TGF-β EffectsonThyroid Cell Physiology
TGF-β is synthesized as an inactive precursor that can be
activated by diﬀerent proteases produced by thyrocytes.
Its expression is upregulated during TSH-induced thyroid
hyperplasia in rats, suggesting that an increased local expres-
sion of TGF-β1, during thyroid hyperplasia, may contribute
to the temporal stabilization of goiter size [65]. TGF-β
signalling is propagated via cell surface serine/threonine
kinases, TGF-β type I receptor (TβRI) and TGF-β type II
receptor (TβRII). Both receptors are expressed on thyrocytes
at equimolar amount [66] and, upon ligand binding by
type II receptor, TβRI is recruited to an heteromeric com-
plex and phosphorylated by TβRII, thus activating its ser-
ine/threonine kinaseinordertophosphorylate thetranscrip-
tion factors R-Smads (Smad2 and Smad3). The phosphory-
lated Smad2 or Smad3 associate with the common partner
Co-Smad, Smad4, forming complexes that accumulate in the
nucleus,wheretheyregulatetargetgenesexpression eitherby
interacting with other transcription factors and coactivators
orcorepressorsorbydirectlybinding todeﬁnedsequencesin
the promoter[67].In contrast to R-Smads and Co-Smad, the
Inhibitory Smads (I-Smads), including Smad6 and Smad7,
bind to TβRI and compete with R-Smads for activation by
TβRI resulting in the inhibition of TGF-β signalling [68, 69].
A Smad ubiquitin regulatory factor 1 (Smurf1), being a
HECT-type E3 (Homologous to the E6-AP C Terminus)
ubiquitinligase, interactswith inhibitorySmad7andinduces
cytoplasmic localization of Smad7. Smurf1, then, associates
with TβRI and enhances the turnover of this receptor [70]
(Figure 2).
TGF-β is the important negative regulator of thyrocyte:
it antagonizes the mitogenic eﬀects of the main growth
factors in cultured cells of human [65, 71], dog [72], pig
[73], and rat origin [4, 74]. TGF-β delaysprogression during
the mid–late G1 phase by directly controlling cyclin D1-3
levels and preventing the relocalization of p27/kip1 inhibitor
from cyclin E/cdk2 to cyclin D3/cdk4 complexes [72, 74].
TGF-β has been shown to downregulate the expression of
thyroid-speciﬁc genes in the majority of species. The iodideJournal of Thyroid Research 5
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Figure 2: Intracellular signal transduction of TGF-β signalling. TGF-β ligand binds to TβRI and TβRII to constitute active heterodimers
that possess serin-threonin kinase activity. Activated TβRI phosphorylates Smad2 and Smad3, which in turn form a complex with Smad4.
Smad2 or Smad3/Smad4 complex translocates into the nucleus where interacts with other DNA-binding transcription factors, coactivators
and corepressors, regulating the transcription of target genes.
trapping is inhibited in rat thyroid cells by blocking the
protein kinase A (PKA) pathway, but not the PKA-induced
DNA synthesis [75] .M o r e o v e r ,w eh a v ed e m o n s t r a t e dt h a t
the overexpression of ErbB2 in FRTL-5 cells, responsible
of the resistance to the inhibitory action of TGF-β on cell
proliferation, does not aﬀect the inhibition of iodide uptake
caused by TGF-β [66]. This eﬀect was likely due in part to
theinhibition oftheexpression of NISmRNAand itsprotein
[76, 77] and in part to the inhibition of the expression
and activity of the Na+/I- ATPase, an enzyme that plays
a key role in iodide uptake [78]. Similar responses have
also been observed in porcine cell cultures, where TGF-β
inhibits iodide uptake and metabolism, cAMP formation,
and T4 release [41]. In human thyroid primary cultures,
TGF-β inhibits most eﬀects of cAMP on gene expression
[79]. The rat thyroid cell lines represent a good model to
study the TGF-β action in regulating the TG expression
respect to porcine thyroid follicular cells where, TGF-β has
no eﬀect [80]. In the FRTL-5 rat thyroid epithelial cell
line, the addition of TGF-β inhibits Pax8 mRNA causing
a decreased formation of Pax8/DNA complexes, both with
or without the addition of TSH that is responsible of the
TGFβ1-induced suppression of TG gene expression [81]. In
the same cells, it has been demonstrated that the inhibition
of TG biosynthesis and TSHR expression by TGF-β1 could
be counterbalanced by blocking the nuclear translocation of6 Journal of Thyroid Research
Smad2 and Smad4 [82]. Instead, Smad3 has a key role in the
reduction of NIS expression, because its physical interaction
with Pax8 in turn diminishes Pax8 binding to DNAsequence
involved in the regulation of NIS [83].
In porcine thyroid cells cultured in suspension, TGF-β
counteracts TSH positive eﬀect on folliculogenesis causing
an inversion of cell polarity [84]. The ability of TGF-β to
modulate cytoskeleton organization and extracellular matrix
protein distribution has been demonstrated not only in
porcine thyroid cells, where it stimulates the expression
of plasminogen activator inhibitor-1 (PAI-1), clusterin,
trombospondin-1 [80, 85, 86], but also in rat thyroid cells
[87]. Finally, in the same cellular model TGF-β1 inhibits
the major histocompatibility complex (MHC) class I by
regulating two elements at the transcription start site of the
ﬂanking region and increases the downstream regulatory
element (DRE) binding of an ubiquitously expressed Y-box
protein, termed TSEP-1 (TSHR suppressor element-binding
Protein-1), an important suppressor of the TSHR and of
MHC class I and class II expression [88]. TGF-β1s t i m u l a t e s
monocyte chemoattractant Protein-1 (MCP-1) and colony-
stimulating factor (CSF) [89], as well as endothelin and its
receptors in human thyroid follicular cells [90].
Therefore, it can be concluded that TGF-β exerts an
important eﬀect on thyroid cells in all the species tested,
inhibiting the proliferation and function and modulating
extracellular matrix (ECM) formation.
6.RoleofTGF-β inThyroidCancer
The inhibition of cellular proliferation is one of the primary
action of the TGF-β signalling. This factor is involved in the
regulation of other numerous cellular functions as embryo-
genesis, diﬀerentiation, apoptosis, angiogenesis, immuno-
suppression, and wound-healing process [91]. Given the
multifunctional role of TGF-β, any aberration of its normal
signalling cascade may have wide-ranging pathologic conse-
quences. Yet, paradoxically, TGF-β also modulates processes
such as cell invasion and microenvironment modiﬁcation
that cancer cells may exploit to their advantage. Conse-
quently, the output of a TGF-β response is highly contextual
throughout development,across diﬀerenttissues, and also in
cancer [92].
Thyroid cancer incidence has signiﬁcantly increased
during the past decades [93], and it has become one of the
ten leading cancer types in females being more frequent
than ovarian, urinary, bladder, or pancreas cancer [94].
Although the majority of thyroid cancers have an excellent
prognosis, there are a small percentage of cases that show
an extensive local invasion and distant metastases, which
frequently do not respond to standard treatments and have a
worsened prognosis. The genetic basis for the initiation and
developmentofthecommontypeofthyroidcancer,papillary
thyroid carcinoma (PTC), is well characterized. It has been
demonstrated that the activation of oncogenes like RAS,
BRAF, RET/PTC, and PI3K/AKT plays an important role in
thyroid tumorigenesis [95]. However, it is also interesting to
underscore the diﬀerences among the tumors arising from
the diﬀerent mutations. Studies in vitro and in vivo have
clearly shown that other oncoproteins, like EGF and TGF-
β, exert their own oncogenic drive, conferring a distinct
biological behaviour on thyroid tumors. The homoeostasis
of growth in diﬀerentiated epithelia reﬂects a critical balance
between the promotion and suppression of cell division. The
thyroid gland is among the most common sites of epithelial
hyperplasia, aﬀecting up to 15% of the adult population,
typically presenting as “sporadic” or multinodular nontoxic
Goiter (MNTG), the hyperplastic gland usually contains
well-deﬁnednodulesofvarying size,surroundedbyanormal
epithelium. A wide range of studies has revealed evidence
for an involvement of several autocrine growth stimulators
and their receptors in the progression of MNTG. Prominent
among these is TGF-β, and a lack of response to TGF-β
inhibitory action in thyroid cells may be responsible for
some cases of MNTG in human cells [71]. In rats, thyroid
hyperplasia induced by iodide deﬁciency and goitrogen is
accompanied by an increase in TGF-β1 expression and the
arrest of goiter growth after 4 weeks. This surprising result
is thought to reﬂect a critical role of TGF-β1i ns t a b i l i z i n g
goiter mass [65, 96]. This would suggest that the increase
in TGF-β1 levels observed during goiter induction might
be a mechanism to counteract the goitrogenic eﬀect of
endogenous TSH [65, 97]. Instead, in a group of patients
with either papillary adenomas (n = 14) or carcinomas
(n = 14), not signiﬁcant changes in blood levels of TGF-β1
have been observed compared to normal controls [98].
Increased expression of TGF-β,N F k B( n u c l e a rf a c t o ro f
κB), and CDC42, compared to the normal thyroid tissue,
has been demonstrated in a group of human papillary
thyroid carcinomas, analyzed by oligonucleotide microarray
of microscopically dissected intratumoral samples from
central and invasive regions. These data together with
reduced levels of mRNAs encoding proteins involved in cell-
cell adhesion and communication and an overexpression
of vimentin strongly support the hypothesis that the TGF-
β, responsible of epithelial mesenchymal transition (EMT)
induction, increases the tumor invasiveness in papillary
thyroid carcinomas [95].
Perturbations of TGF-β signalling are central to tumori-
genesis and tumor progression. TβRII is commonly inacti-
vated through mutation and loss of heterozygosity (LOH)
in several types of carcinoma [99]. Lazzereschi et al. [100],
have obtained similar results in a series of human thyroid
tumors, from benign lesions (adenomas) to neoplastic
lesions of increasing aggressiveness (papillary and follicu-
lar carcinomas) up to the extremely aggressive anaplastic
tumors. Northern blot analyses demonstrated a statisti-
cally signiﬁcant reduction (about 2-3-fold less) of TβRII
expression in papillary thyroid carcinomas in comparison
with the respective healthy tissues. Immunostaining of the
formalin-ﬁxed sections with speciﬁc anti-TβRII antibodies
substantiates these data, clearly demonstrating that the
greatest reduction in TβRII immunoreactivity was found
in the highly malignant, undiﬀerentiated anaplastic thyroid
tumors. A comparative study performed in diﬀerent types
of epithelial thyroid carcinomas of patients from diﬀerent
regions oftheworld demonstrated astrongdecreaseofTβRIIJournal of Thyroid Research 7
expression in follicular cancer of patients from China, Japan,
and USA (50%, 55%, and 90% respectively). In papillary
thyroid carcinoma TβRII was decreased in 75%, 77% and
96% of patients from Japan, China, and USA, respectively.
Finally, in undiﬀerentiated cancer, the reduction of TβRII
expression was observable in 83% of patients from USA and
in 100% of patients from China [101].
Inactivating mutations in Smad2 and 4 are frequently
found in some cancers [102]. In a group of 20 follic-
ular thyroid neoplasms, classiﬁed as 11 adenomas and
9 minimally invasive follicular carcinomas, according to
current pathological criteria, Smad2 expression investigated
byimmunohistochemistry has beenlost,whileTβRIIexpres-
sion was lost in 78%. These data indicate that the downreg-
ulation of TβRII remains the major consistent abnormality
in thyroid carcinomas that may be used to diﬀerentiate
minimally invasive carcinomas from adenomas, while the
downregulation of Smad2 could be another mechanism
by which carcinomas become independent from TGFβ–
mediated growth inhibition [103].
The tumor suppressor role of TβRII has been demon-
strated in vitro in a model of K-ras transformed rat thyroid
cells, where the overexpression of TβRII induces not only
a partial reversion of malignant phenotype restoring the
sensitivity to TGF-β, butalso a signiﬁcant reduction in spon-
taneous and lung artiﬁcial metastases when transplanted in
athymic nude mice [104]. In this model, the overexpression
of TβRII is essential to reduce the invasive potential and
to modulate the adhesive and migratory cell behaviours
by controlling the integrin functions rather than integrin
receptor expression [105]. The inhibitory action of TGF-β1
on cellular migration, invasion, and adhesion is present in a
set of human PTC and follicular thyroid carcinoma (FTC)
cell lines, while inhibition of TGFβ-induced cell growth
is maintained only in FTC cell lines [106]. Other authors
demonstrated that in human papillary thyroid carcinoma
cell line TPC-1, these eﬀects are probably due to the lower
level of Smads 2, 3, and 4 associated to an increase in Smad7
expression [107]. Otherwise, the altered expression of TGF-
β pathway proteins not always is responsible of resistance to
the TGF-β action. A human anaplastic carcinoma cell line,
despite the activity of receptors signalling, Smad2 phospho-
rylation and nuclear translocation of Smad2/4 complexes, is
strongly resistant to the TGF-β action, suggesting that other
signalling mechanisms might be related to the escape from
TGF-β sensitivity [108].
Sensitivity to TGF-β is impaired in thyroid tumors and
escape from TGF-β action is actively selected during thyroid
tumor development. Destruction of the TGF-β signalling
at the level of Smad genes is common in human carcino-
mas, the deﬁciencies of Smad4 have been hypothesized to
underlie TGF-β resistance of tumor cells and to strongly
accelerate the malignant progression of neoplastic lesions
initiated by other oncogenic stimuli [92]. Lazzereschi et
al. [109] showed, for the ﬁrst time, the mutational and
the expression status of Smad4 in a consistent number of
thyroid tumors of diﬀerent histotypes, demonstrating the
high frequency of Smad4 abnormalities (27%) in thyroid
tumors, comparable only with Smad4 mutation frequency in
tumors arising from the gastrointestinal tract, both sporadic
and inherited. The high frequency of alterations in Smad4
sequence led the authors to propose that these changes may
constitute a nearly and frequent event in thyroid tumors
natural history. Smad4 inactivation in tumors is generally
a late event linked to progression to overt carcinoma. In
human papillary thyroid cell lines, TPC-1 and BCPAP,
it has been recently demonstrated a strong reduction in
the level of SMAD4 protein, which is responsible for
an alteration of TGF-β signalling and for some of the
TGF-β-mediated biological eﬀects. The overexpression of
Smad4, restoring TGF-β signal transduction, determines a
signiﬁcant increase of antiproliferative response to TGF-
β, reduces the invasive behaviour of these cells as well
as is responsible of a signiﬁcant increase of E-cadherin
expression, indicating that the level of SMAD4 is a critical
regulator of these processes. To remark the important role
of SMAD4 in thyroid carcinogenesis contributes also the
ﬁnding obtained by immunohistochemistry that 7 out of
23 (30%) PTC tumor samples, including 1 case of follicular
variantofPTCs,presentaweak andfocalintensityofSMAD4
staining compared to normal tissue from the opposite lobe
[110].
The stability of TβRI represents an important regulatory
mechanism for TGF-β signalling both in cell culture studies
and in vivo models. TGF-β receptors are ubiquitinated and
degraded through the action of several cooperating protein
complexes containing E3 ligases as well as other important
regulators of protein degradation. The I-Smads regulate
many of these complexes, orchestrating both ubiquitination
and de-ubiquitination [111]. The levels of Smurf1 and
Smad7are overexpressed in theanaplastic thyroidcarcinoma
cell line [112], and an increase of SMAD7 expression
has been found in a group of papillary and follicular
carcinomas with respect to benign pathologies, indicating
SMAD7as another SMADinvolvedin thyroid tumorigenesis
[113].
It is known that TGF-β’s role in human cancer appears
both complex and context depended. Depending on the
tumortypeandthestageoftumorprogression,itcanexercite
strong tumor suppressive or tumor-promoting functions.
More recently, it has been demonstrated that also in thyroid
cells, as well as in the skin tumors, or in metastatic colon
cancer [114], TGF-β can acts as tumor-promoting factor.
The expression of BRAFV660E,in normal rat thyrocytes and
in ﬁfty cases of human PTC determines a reduction of NIS
expression and an increase of TGF-β secretion, suggesting an
hyperactivation of TGF-β signalling, responsible of the pro-
tumorigenic activity [115].
The aberrant microRNA (miR) expression, involved in
the cell growth suppressive function, has been demon-
strated in a large number of follicular thyroid neoplasias
[116]. More recently, a new important function of TGF-
β, involving the regulation of expression of miR levels
(miR-200 and miR-30), has been discovered in human
anaplastic thyroid carcinoma (ATC). ATCs represent a more
aggressive type of thyroid cancer arising from mesenchymal
de-/transdiﬀerentiationofepithelialthyroidcellsthatrapidly
invade the adjacent tissue. The main function of miR-2008 Journal of Thyroid Research
and miR-30 is to negatively regulate the EMT process in
follicular cells. The low levels of miR-200 and miR-30 in
ATCs respect to that observed in thyroid normal tissues, in
PTCs or in FTCs, strongly suggest that the invasive potential
of ATC is due to enhancement of EMT process. In addition,
it has been demonstrated that the reduction of miR-200 and
miR-30 in these carcinomas is caused by a strong activation
of TGF-β signalling due to an upregulation of TβRI and
Smad2. Therefore, the authors not only propose a novel
molecular panel to identify ATCs, but also they suggest
the inhibition of TGF-β signalling represent a new likely
approach for the treatment of these carcinomas [117].
7.GrowthFactorsCross-TalkinThyroid:
Role of TGF-β andEGF Systemsin
theRegulationofThyroid Growth
Complex and apparently redundant interactions between
hormones and growth factors regulate thyroid cell pro-
liferation and diﬀerentiation. However, information about
the cross-talk between diﬀerent growth factors that regulate
thyroid cell growth is limited. Ariga et al. [118] studied
the signalling pathway through which the synergistic actions
between IGF-I and TSH are mediated in FRTL-5 cells. Also,
TGF-β1 and IGF-I appear to interact and have opposite
eﬀects on the growth of rat thyroid cells [75]. In particular,
TGF-β1 attenuates IGF-I-stimulated MAPK phosphoryla-
tion through inhibition of IRS-1 (insulin receptor substrate-
1) tyrosine phosphorylation, IRS-1/Grb2/Sos complex for-
mation and CrkII tyrosine phosphorylation thus leading to
the suppression of FRTL-5 cell growth [119]. ErbB ligands
and ErbB receptors provide a complex and multilayered
network of signalling that is deregulated in many human
tumors. However, several are the causes and mechanisms
of uncontrolled signalling by ErbB receptors suggesting that
diﬀerences exist within the ErbB family in the mechanism
of regulation but also in the cross-talk with other growth
factors.
TGF-β is involved in two opposing activities: it is able to
function as a growth inhibitor at early stages of carcinogene-
sis andas agrowthpromoteratlaterstages ofneoplasia when
tumor cells that have developed the capability to bypass the
tumor inhibitor function of TGF-β, paradoxically, may use
it for tumor progression by means of multiple mechanisms.
Overexpression of TGF-β ligands has been reported in
most cancers [120] and correlates with markers of a more
metastatic phenotype and/or a poor patient outcome. This
dual role of TGF-β is believed to result from molecular
cross-talk with a complex network of signalling pathways
involving either direct eﬀects on tumor cells or paracrine
eﬀectsonothercells[121].Severalreportsprovidedevidence
that TGF-β can collaborate with EGF/ErbB receptors system.
Indeed,ithasbeenshown thatSmadsproteinsmaycross-talk
with mitogenic growth-factor signalling through receptor
tyrosinekinase-inducedMEK/MAPKproteinkinasesbothin
asynergistic(MEK1-inducedSmad2phosphorylation)[122]
or an antagonistic interplay (MAPK-induced Smad1 phos-
phorylation) [123, 124]. In tumors, ErbB receptors and their
ligandspromotegrowthandconferapoptosisresistance,thus
overcoming TGF-β1 growth inhibition and apoptotic eﬀect.
Indeed, in rat hepatocytes an autocrine loop of TGF-β in
cells that have undergone EMT, induces an upregulation of
EGFR/ErbB1 ligands by promoting their shedding through
theactivationofADAM17(adisintegrinandmetalloprotease
17) and thus allowing some cells to escape from TGFβ-
induced pro-apoptotic eﬀect [125, 126]. A further mech-
anistic insight on the conversion of the function of TGF-
β from tumor suppressor to tumor promoter has been
provided by the evidence that the EGF signalling pathway
may enhance TGF-β responses. EGF increases the stability
of TβR I It h u sp r e v e n t i n gf u l ll o s so fT βRII expression in
late stage of cancers, and thereby permits some of the direct
oncogenic behaviour of TGF-β during tumor progression
[127]. Uttamsingh et al. [128] showed that in conjunction
with EGF, TGF-β1 helps to augment migration, invasion
and anchorage-independent growth of intestinal epithelial
cells, in agreement with reports indicating that activation
of TGF-β signalling promotes pulmonary metastasis of
mammary tumors in neu transgenic mice [129]. Moreover,
the elevated and prolonged activation of ERK/MAPK and
i t sr e q u i r e m e n tf o rE G Fa n dT G F β1-induced EMT and
migration/invasion of intestinal cells is in agreement with
that between ErbB2 and TGF-β1 in mammary epithelial
cells [130]. In ﬁbroblasts, TGF-β induces the upregulation
of ErbBs ligands and activation of cognate receptors via the
canonical Smad pathway, thus allowing the induction of
ﬁbroblast cell morphologic transformation and anchorage-
independent growth [131].
Contrasting to this plethoraofdata oncross-talk between
EGF and TGF-β1 signals, there are very few results in the
literature relating the interconnection between EGF and
TGF-β signalling pathways in thyroid cancer cells.
Rat thyroid epithelial cells overexpressing the ErbB2
proto-oncogene are not transformed in vitro but no longer
depend on TSH for cell growth and become resistant to
the growth inhibitory eﬀects of TGF-β1, thus suggesting
that ErbB2 proto-oncogene, when overexpressed, is able to
interfere and cross-talk with growth factors that control in
a positive and negative manner the thyroid cell proliferation
[132]. Using collagen gel-cultured porcine follicles, Nilsson
et al. [133] demonstrated that the morphoregulatory eﬀects
of EGF are highly inﬂuenced by TGF-β1. In particular,
TGF-β1 inhibits EGF-induced thyrocytes proliferation, but
it synergizes with EGF in the stimulation of cell migration.
This latter eﬀect could be due to the known role of TGF-
β1 to regulate the cell-matrix interactions, by stimulating
the synthesis of extracellular matrix components, inhibit-
ing proteases and inducing changes of integrin synthesis.
However, contrasting to these results, TGF-β1 inhibited both
EGF-induced mitogenesis and motogenesis in rabbit corneal
epithelial cells [134] indicating that the modulation by TGF-
β1 of EGF responses diﬀers among epithelial cell types.
Moreover, in a follicular thyroid cancer cell line lacking
endogenous TSHR, EGF, and TGF-β have been shown
to enhance VEGF (vascular endothelial growth factor)
secretion. Since the loss of the TSHR is characteristic of
anaplastic thyroid cancer, which usuallyexhibitssigniﬁcantlyJournal of Thyroid Research 9
increasedVEGFexpression andahighdegreeofangiogenesis
compared with diﬀerentiated thyroid cancer, the ﬁnding
of VEGF stimulation by EGF and TGF-β, highlights the
important role of these growth factors in thyroid tumor
progression and aggressiveness [135]. Preliminary data from
our laboratory demonstrate that cotreatment with EGF and
TGF-β1 results in opposite eﬀects in human thyroid cancer
cell lines. Indeed, TGF-β1 inhibits EGF-mediated migra-
tion in invasion/wound healing assay, while a synergistic
eﬀect between TGF-β1 and EGF is observed in anchorage-
independent growth assay. These ﬁndings demonstrate that
cell invasion and anchorage-independent growth capability
involve diﬀerent factors and molecular mechanisms (Min-
cione G. et al., unpublished results).
8.Conclusions
The ﬁndings described in this paper support the hypothesis
that a network formed by the EGF/ErbBs system and TGF-
β pathway is involved in the pathogenesis and progression
of thyroid tumors. Further understanding of the complexity
of cross-talk between these pathways in thyroid disease
related to gain of function of ErbB, inactivation of growth
suppression function, or activation of tumor promoter
activity of TGF-β1w i l lo ﬀer a broader spectrum of points of
intervention and will lead to continued advances in thyroid
cancer treatment.
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